AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1254157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Endoxan)
Number of subjects: 1022
Study 1254157 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical operation during remission
Number of subjects: 1022
Study 1254157 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chemotherapy for at least 2 years
Number of subjects: 1022
Study 31609644 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist Response Questionnaire for Adolescents (TRQ‐A)
Number of subjects: 192
Study 30692875 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Remifentanil
Number of subjects: 0
Study 30692875 — intervention group
Group type: COMPARATOR
Intervention: Low-Dose Remifentanil
Number of subjects: 0
Study 26427789 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Matricaria recutita L (chamomile) oil
Number of subjects: 80
Study 26427789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26123824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg plus tramadol hydrochloride 75 mg
Number of subjects: 606
Study 26123824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 12.5 mg plus tramadol hydrochloride 37.5 mg
Number of subjects: 606
Study 26123824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg
Number of subjects: 606
Study 26123824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 75 mg
Number of subjects: 606
Study 26123824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 37.5 mg
Number of subjects: 606
Study 26123824 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 606
Study 26123824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 23853029 — intervention group
Group type: EXPERIMENTAL
Intervention: AFQ056 200 mg daily
Number of subjects: 133
Study 23853029 — intervention group
Group type: EXPERIMENTAL
Intervention: AFQ056 50 mg daily
Number of subjects: 133
Study 23853029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 21637908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 0
Study 21637908 — intervention group
Group type: COMPARATOR
Intervention: Medical device foam (ceramide-hyaluronic acid emollient)
Number of subjects: 0
Study 18995935 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nasolabial flaps and coronoidectomy
Number of subjects: 47
Study 18995935 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative physiotherapy
Number of subjects: 47
Study 17207303 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 443
Study 17207303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen 7.5/750 mg
Number of subjects: 443
Study 17207303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 15515415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tropisetron
Number of subjects: 34
Study 15515415 — intervention group
Group type: COMPARATOR
Intervention: 40 mg methylprednisolone
Number of subjects: 34
Study 11556458 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine
Number of subjects: 19
Study 11556458 — intervention group
Group type: COMPARATOR
Intervention: Non-treated eyes
Number of subjects: 19
Study 9628270 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin administered i.v. by continuous infusion for 7 days, followed by daily s.c. injections for 6 months. Intravenous insulin infusions were repeated every 12 months.
Number of subjects: 14
Study 9628270 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated individuals).
Number of subjects: 14
Study 7931953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal bovine surfactant prophylaxis
Number of subjects: 64
Study 7931953 — intervention group
Group type: COMPARATOR
Intervention: Air control
Number of subjects: 64
Study 2904931 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 4.4 mg
Number of subjects: 12
Study 2904931 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 8.8 mg
Number of subjects: 12
Study 2904931 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 17.6 mg
Number of subjects: 12
Study 2904931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30597523 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction and IVF treatment (n = 160)
Number of subjects: 317
Study 30597523 — intervention group
Group type: COMPARATOR
Intervention: IVF only (n = 157)
Number of subjects: 317
Study 28024165 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse adhesive
Number of subjects: 52
Study 28024165 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimode universal adhesive
Number of subjects: 52
Study 28024165 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive
Number of subjects: 52
Study 28024165 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional acid etching
Number of subjects: 52
Study 28024165 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study 26432647 — intervention group
Group type: EXPERIMENTAL
Intervention: remedē System therapy initiated at 1 month after implantation
Number of subjects: 173
Study 26432647 — intervention group
Group type: COMPARATOR
Intervention: Inactive remedē System for 6 months (control)
Number of subjects: 173
Study 26432647 — intervention group
Group type: EXPERIMENTAL
Intervention: remedē System therapy
Number of subjects: 173
Study 26432647 — intervention group
Group type: COMPARATOR
Intervention: Inactive remedē System (control)
Number of subjects: 173
Study 23354337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand
Number of subjects: 3
Study 23354337 — intervention group
Group type: COMPARATOR
Intervention: Intubating LMA
Number of subjects: 3
Study 23354337 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 3
Study 21071527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula with continuous flow at 2 L/min
Number of subjects: 16
Study 21071527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula with oxygen-conserving device at 2 L/min
Number of subjects: 16
Study 21071527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula with portable oxygen concentrator at 2 L/min
Number of subjects: 16
Study 19864035 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE) with zinostatin stimalamer and gelatin sponge
Number of subjects: 161
Study 19864035 — intervention group
Group type: COMPARATOR
Intervention: Transarterial infusion chemotherapy (TAI) with zinostatin stimalamer
Number of subjects: 161
Study 16887301 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5mg/day)
Number of subjects: 0
Study 16887301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15293609 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 23
Study 15293609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11824325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radio-chemotherapy (cisplatin 75 mg/m2 d1, etoposide 120 mg/m2 d1-3, Ifosfamid 1.5 mg/m2 d1-4, 3 cycles)
Number of subjects: 58
Study 11824325 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (5 x 2 Gy/50 Gy)
Number of subjects: 58
Study 9734346 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeze with bronchial hyperreactivity
Number of subjects: 252
Study 9734346 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive measures for progression from asymptomatic BHR to asthma
Number of subjects: 252
Study 7818058 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 30
Study 7818058 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4 mg.kg‐1
Number of subjects: 30
Study 7818058 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1
Number of subjects: 30
Study 2466389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4.5 micrograms kg‐1 orally 2 hours before operation (Group I)
Number of subjects: 42
Study 2466389 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4.5 micrograms kg‐1 orally 4 hours before operation (Group II)
Number of subjects: 42
Study 2466389 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg kg‐1 orally 2 hours before operation (Group III)
Number of subjects: 42
Study 2466389 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet 2 hours before operation (Group IV)
Number of subjects: 42
Study 30332546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 0
Study 30332546 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 29439691 — intervention group
Group type: EXPERIMENTAL
Intervention: Option Grid
Number of subjects: 1100
Study 29439691 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture Option Grid
Number of subjects: 1100
Study 29439691 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1100
Study 26882102 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon α1b therapy (rHuIFN‐α1b)
Number of subjects: 0
Study 26882102 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24452659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 1500 IU (HYL)
Number of subjects: 25
Study 24452659 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NSL)
Number of subjects: 25
Study 22889285 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser as an adjunct to mechanical debridement
Number of subjects: 30
Study 22889285 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical debridement
Number of subjects: 30
Study 19902489 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month buddy intervention
Number of subjects: 0
Study 19902489 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 17613792 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of differential contextual information at test
Number of subjects: 0
Study 17613792 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized receiver operating characteristic data in terms of z-scores
Number of subjects: 0
Study 17613792 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical indices suggested by Wixted and Stretch (2004)
Number of subjects: 0
Study 17613792 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-factor theory of remember-know and recognition
Number of subjects: 0
Study 17613792 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimisation of bias factors in remember-know methodology
Number of subjects: 0
Study 15915010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol pMDI (cumulative doses up to 96 microg)
Number of subjects: 22
Study 15915010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol DPI (cumulative doses up to 96 microg)
Number of subjects: 22
Study 15915010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15915010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol pMDI
Number of subjects: 22
Study 15915010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol DPI
Number of subjects: 22
Study 15915010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol pMDI and DPI
Number of subjects: 22
Study 12409652 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine with or without a farnesyl transferase inhibitor
Number of subjects: 0
Study 12409652 — intervention group
Group type: EXPERIMENTAL
Intervention: histone deacetylase inhibitor
Number of subjects: 0
Study 12409652 — intervention group
Group type: EXPERIMENTAL
Intervention: capecitabine
Number of subjects: 0
Study 12409652 — intervention group
Group type: EXPERIMENTAL
Intervention: G17DT (antigastrin immunogen)
Number of subjects: 0
Study 12409652 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐nitrocamptothecin (topoisomerase I inhibitor)
Number of subjects: 0
Study 12409652 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaliplatin to high‐dose 5FU plus leucovorin
Number of subjects: 0
Study 12409652 — intervention group
Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid (fish oil)
Number of subjects: 0
Study 12409652 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin plus ursodeoxycholic acid
Number of subjects: 0
Study 10447843 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured learning materials
Number of subjects: 228
Study 10447843 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 228
Study 7589056 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporin at 200 mg
Number of subjects: 5
Study 7589056 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporin at 800 mg
Number of subjects: 5
Study 2237853 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-150 mg acetylsalicylic acid per day for prophylaxis after acute myocardial infarction
Number of subjects: 0
Study 2237853 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg acetylsalicylic acid for cerebrovascular indications
Number of subjects: 0
Study 109916 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg disodium cromoglycate (DSCG) inhaled with a spinhaler 30 minutes before exercise
Number of subjects: 16
Study 109916 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of ketotifen taken orally 3 hours before exercise
Number of subjects: 16
Study 109916 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder inhaled with a spinhaler
Number of subjects: 16
Study 109916 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 16
Study 31769533 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten (6-g gluten protein)
Number of subjects: 36
Study 31769533 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 36
Study 29253167 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable cameras used to assess sun-protective behaviours and shade availability during school lunch-breaks.
Number of subjects: 168
Study 29253167 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable cameras for assessing specific sun-protective behaviours.
Number of subjects: 168
Study 29253167 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of shade structures using wearable cameras.
Number of subjects: 168
Study 28117400 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterols-enriched low-fat milk (1.5 g phytosterols per day)
Number of subjects: 221
Study 28117400 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-fat milk
Number of subjects: 221
Study 25449559 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted step training (RAST)
Number of subjects: 23
Study 25449559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 23
Study 23702253 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed extract (GSE) 300 mg/d
Number of subjects: 70
Study 23702253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 70
Study 21854344 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training
Number of subjects: 27
Study 21854344 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive resistance training
Number of subjects: 27
Study 21854344 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle endurance training
Number of subjects: 27
Study 19473453 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 218
Study 19473453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 17953695 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6, TNF-A and LT-A gene polymorphisms
Number of subjects: 96
Study 17953695 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6, TNF-A and LT-A gene polymorphisms in high responder (HR) subgroup
Number of subjects: 96
Study 17953695 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6, TNF-A and LT-A gene polymorphisms in low responder (LR) subgroup
Number of subjects: 96
Study 15535409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 917
Study 15535409 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 917
Study 15535409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine + Efavirenz (NVP+EFV)
Number of subjects: 917
Study 15535409 — intervention group
Group type: COMPARATOR
Intervention: Adverse events during follow-up
Number of subjects: 917
Study 11206821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic measurement of fibulo‐trochlear angle in neutral position and under inversion stress
Number of subjects: 0
Study 9272408 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral ketotifen daily
Number of subjects: 48
Study 9272408 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral ketotifen daily
Number of subjects: 48
Study 7871077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg sarmazenil
Number of subjects: 12
Study 7871077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sarmazenil
Number of subjects: 12
Study 7871077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3544792 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil-SR, 240 mg twice daily
Number of subjects: 12
Study 3544792 — intervention group
Group type: EXPERIMENTAL
Intervention: regular formulation of verapamil, 120 mg 4 times daily
Number of subjects: 12
Study 3544792 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30300003 — intervention group
Group type: COMPARATOR
Intervention: Breath-held MRE
Number of subjects: 25
Study 30300003 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-breathing MRE
Number of subjects: 25
Study 30300003 — intervention group
Group type: EXPERIMENTAL
Intervention: CS accelerated 2D GRE MRE
Number of subjects: 25
Study 26462707 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS 914392 (10 mg OD)
Number of subjects: 20
Study 26462707 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS 914392 (10 mg TDS)
Number of subjects: 20
Study 26462707 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS 914392 (20 mg TDS)
Number of subjects: 20
Study 26462707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24565698 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells (MSCs)
Number of subjects: 6
Study 24565698 — intervention group
Group type: COMPARATOR
Intervention: Revascularization alone
Number of subjects: 6
Study 24565698 — intervention group
Group type: COMPARATOR
Intervention: Nontreated segments
Number of subjects: 6
Study 22394528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue management program
Number of subjects: 181
Study 16202723 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg vaginally)
Number of subjects: 34
Study 16202723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaginally)
Number of subjects: 34
Study 12243291 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine injection after combined spinal anaesthesia
Number of subjects: 30
Study 12243291 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine injection after epidural anaesthesia
Number of subjects: 30
Study 10328327 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 14
Study 10328327 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 14
Study 7560628 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg, n = 22)
Number of subjects: 59
Study 7560628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (100 mg three times a day, n = 19)
Number of subjects: 59
Study 7560628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 59
Study 1963183 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg twice daily)
Number of subjects: 15
Study 1963183 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg once daily)
Number of subjects: 15
Study 1963183 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem plus Atenolol
Number of subjects: 15
Study 1963183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1963183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Diltiazem + Atenolol)
Number of subjects: 15
Study 1963183 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem alone
Number of subjects: 15
Study 1963183 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol alone
Number of subjects: 15
Study 1963183 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study 7025777 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 17
Study 7025777 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 17
Study 31081575 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs published from 2008 to 2017
Number of subjects: 96
Study 31081575 — intervention group
Group type: COMPARATOR
Intervention: RCTs published from 1988 to 1997
Number of subjects: 96
Study 28257920 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized web‐based counseling and decision support tool
Number of subjects: 1250
Study 28257920 — intervention group
Group type: COMPARATOR
Intervention: Standard educational content
Number of subjects: 1250
Study 26081471 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐loop
Number of subjects: 38
Study 26081471 — intervention group
Group type: EXPERIMENTAL
Intervention: υ‐loop
Number of subjects: 38
Study 26081471 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 38
Study 23789564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 0
Study 21694614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (300, 600, or 1200 mg)
Number of subjects: 433
Study 21694614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (plasma concentrations > 1660 ng/mL)
Number of subjects: 433
Study 21694614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433